Immune Response to Influenza Vaccine in Islet Cell Transplant Recipients
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for organ transplant patients, studies have shown that the standard inactivated influenza vaccine has poor immunogenicity in this population. The investigators plan to test the humoral response to vaccination and look at HLA upregulation
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Humoral Immune Response To Influenza Vaccine In Islet Cell In Transplant Recipients|
- •Seroprotection rate [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]defined as a post-vaccination titer of ≥1:40
- •Seroconversion rate [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]defined as a 4-fold increase in titer from pre- to post-vaccination.
|Study Start Date:||August 2010|
|Study Completion Date:||December 2011|
|Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
|islet cell transplant recipients|
OBJECTIVE AND HYPOTHESIS
- To test the specific humoral response of the influenza vaccine after islet cell transplantation
- To test the production of HLA alloantibodies after vaccination.